Table 5.
Estimates of change from baseline in protein-based high-density lipoprotein (HDL) subspecies associated with coronary heart disease risk. Panel A. Absolute change from baseline in HDL subspecies associated with coronary heart disease risk
| Variable | 1 mg/d | 5 mg/d | 15 mg/d | Placebo | P, 5 mg/d vs placebo | P, any effect |
|---|---|---|---|---|---|---|
| Total plasma APOA1 concentration, mg/dL | –17.15 (–34.47 to 0.17) | –38.87 (–56.23 to –21.50) | –55.64 (–72.06 to –39.23) | 4.91 (–11.92 to 21.75) | < .001 | < .001 |
| APOA1 concentration (mg/dL) of HDL that contains α2-macroglobulin, mg/dL | –1.03 (–1.68 to –0.39) | –1.43 (–2.07 to –0.79) | –1.28 (–1.92 to –0.65) | 0.04 (–0.60 to 0.69) | .001 | .005 |
| APOA1 concentration (mg/dL) of HDL that contains APOC1 | –5.21 (–9.07 to –1.36) | –5.09 (–8.85 to –1.33) | –8.43 (–12.21 to –4.65) | –0.27 (–4.08 to 3.53) | .061 | .032 |
| APOA1 concentration (mg/dL) of HDL that contains APOC3 | –2.84 (–4.70 to –0.99) | –3.38 (–5.19 to –1.57) | –3.42 (–5.20 to –1.64) | –0.63 (–2.45 to 1.18) | .027 | .087 |
| APOA-I concentration (mg/dL) of HDL that contains complement C3 | –1.13 (–1.88 to –0.37) | –1.72 (–2.45 to –0.98) | –2.27 (–2.99 to –1.55) | –0.74 (–1.47 to –0.01) | .053 | .022 |
| APOA1 concentration (mg/dL) of HDL that contains APOE | –3.99 (–7.33 to –0.64) | –8.47 (–11.57 to –5.36) | –7.56 (–10.55 to –4.56) | –0.23 (–3.35 to 2.90) | < .001 | < .001 |
| APOA1 concentration (mg/dL) of HDL that contains plasminogen | –1.19 (–2.22 to –0.15) | –2.36 (–3.38 to –1.33) | –2.94 (–3.91 to –1.97) | –0.40 (–1.39 to 0.59) | .005 | .003 |
Abbreviation: HDL, high-density lipoprotein.